After the First World War, the first National Institute of Health of the Czechoslovak Republic was established on the grounds of a former agricultural facility in Bohumil. Its goal was to develop and produce serum and vaccines and to supervise the quality of food and pharmaceuticals. After the Second World War, the National Institute of Health relocated to Prague and only its serum and vaccines production facility remained in Bohumil, operating under the name of Biogena and later Sevac. Following the Velvet Revolution, it was decided to build a plasma processing plant in Bohumil. However, it was never finished and in 2001, the production facility was acquired by the American company Baxter. From that year until 2015, the facility produced flu vaccines using the advanced serum-free Vero cell technology. Upon the termination of the production programme, the facility became the property of the American company Nanotherapeutics. It was sold by the company in April 2017, with the licence to the Vero cell IPV production technology included, to the newly-established joint stock company PRAHA VACCINES, a member of the Cyrus Poonawalla Group.

The plant is currently undergoing reconstruction to assure that the IPV is manufactured in accordance with the cGMP requirements and the safety regulations defined by the WHO and the Czech legislation for vaccine production.